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Abstract

Diabetes mellitus type 2 (DM2) patients are at risk of episodes of fluctuating blood glucose levels when
in the hospital. On admission at the target practice site, the home dose of oral hypoglycemic medication is
typically stopped and replaced with sliding-scale insulin therapy. Hyperglycemia among the hospital
population of DM2 patients is common, causing delayed healing times, increased length of stay, increased
costs, and other medical detrimental factors.
A doctor of nursing practice project was based on the findings from a randomized controlled trial of a
basal-plus insulin protocol that lowered the mean blood glucose level for noncritically ill hospitalized
DM2 patients. In the trial, adding a long-acting basal insulin to the short-acting insulin sliding scale
yielded a drop in mean blood glucose scores, with minimal risk for hypoglycemia.
A quality improvement project using Lewin’s change theory was planned and implemented using a PlanDo-Study-Act cycle. Initially, 51 patients were started on the protocol; 4 received the protocol for the
duration of their stay. Patients who otherwise qualified for the project were excluded from the project
because of changes made by colleagues, a patient declining doses, patients being admitted to the intensive
care unit, and patients receiving high-dose steroid therapy.
In a comparison with the mean blood glucose level of similar patients who did not receive the protocol,
the mean blood glucose level of the patients who received the protocol decreased during hospitalization
by 25.52 mg/dL; the mean length of stay decreased by 1.75 days. This mean decrease in hospital length of
stay in days equals a decrease in cost of approximately $6973.05. In conclusion, the basal-plus insulin
protocol is straightforward, simple to include in a busy hospital practice, and offers several benefits.
Keywords: Type 2 diabetes mellitus, hospital, hyperglycemia, blood glucose, insulin, slidingscale, basal insulin
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Basal-Plus Insulin Regimen: Helping Patients with Diabetes Mellitus Type 2 to Maintain Blood
Glucose Levels During Hospitalization
For hospitalized diabetes mellitus type 2 (DM2) patients, the consequences of hyperglycemia are
linked with unfavorable outcomes, including death (American Diabetes Association [ADA], 2021).
Agreement among the three largest professional authority organizations with respect to DM2—namely,
the Society of Hospital Medicine (SHM), the ADA, and the American Association of Clinical
Endocrinologists (AACE)—collectively recommended to stop sliding-scale insulin as the only method for
glycemic control (Nau et al., 2010). Conceptually, the insulin sliding-scale has remained a reactive,
chasing method to glucose control, and not a pre-emptive approach to assertively stop hyperglycemic
states. Standards of medical care in diabetes by Bakris (2016) contain the current ADA clinical practice
recommendations for DM2 care and strongly suggest adding basal insulin to each treatment strategy. The
Joint Commission added an accreditation program for hospitalized DM2 patients, and a team-managed
development program was initiated by the SHM (ADA, 2021).
The purpose of this paper is to discuss the results of a quality improvement (QI) project regarding
hospitalized patients with DM2 who are receiving hyperglycemia treatment. This project was intended to
improve healthcare safety and effectiveness by changing personal practice through implementation of a
protocol whose efficacy has been confirmed in a randomized controlled study. Addition of a basal-insulin
protocol and study of outcomes were the primary goals.
Problem Description
Oral hypoglycemic medications that patients with DM2 were taking before hospitalization are
typically stopped upon hospital admission at the target practice site. For coverage, the DNP student
usually orders sliding-scale insulin therapy, a short-acting insulin therapy with a glucometer reading from
finger-stick checks about a half hour before meal times and bedtime. Short-acting insulin enters the
bloodstream in about 30 minutes and lasts 6 hours. Carbohydrate-controlled diets for patients with
diabetes are usually ordered as well.
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Before implementation of the doctor of nursing project (DNP), several hospitalized DM2 patients
were observed by the DNP student to have hyperglycemia, having a blood glucose level greater than 180
mg/dL. Substantial swings in the patient’s blood glucose measurements are not uncommon, predictably
remaining high. Several events that can cause blood glucose levels to rise are stress, inactivity, infection
or illness, and side effects of medications, some or all of which may be experienced as an inpatient during
hospitalization (Pasquel & Umpierrez, 2013). Increased hospital length of stay, cost, morbidity, mortality,
readmission rates, surgical complications, and increased risk of infection are all associated with inpatient
hyperglycemia. If the blood glucose level remains high, the following may occur: potential damage to the
kidneys, cardiovascular system, blood vessels to the retina, or nerves; serious skin infections or skin
ulcers on the feet, sometimes requiring amputation; bone and joint problems; and teeth and mouth
infections (Castro, 2014).
In an effort to improve the mean glucose scores for patients admitted to the Gerald Champion
Regional Medical Center (GCRMC) from January 21, 2022 to February 9, 2022, an evidence-based
quality improvement (QI) project was implemented. The intervention used in the project was a basal-plus
insulin regimen, achieved by adding a long-acting insulin to the short-acting insulin sliding scale. Adding
the long-acting basal insulin was based on findings from a randomized controlled trial from which the
findings had been peer reviewed and published (Umpierrez, Smiley, Hermayer, et al., 2013). In addition
to the patients’ mean blood glucose level during hospitalization, additional measures considered in the
project were length of stay and cost reduction.
Available Knowledge
Pub-Med, CINAHL, Medline, and the Cochrane Database of Systematic Reviews were queried
with the following keywords: Diabetes type 2, hyperglycemia, hospitalized, and insulin. The 430 results
were then further narrowed by specifying the following limiters: humans, ages 45 years and older,
English language, and published within the last 10 years. The result was 125 articles, of which 26 were
randomized controlled trials.
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Hyperglycemia in noncritically ill hospitalized patients has been a topic among hospitalists,
family practice providers, and endocrine specialists. Use of an insulin-only treatment for hospitalized
DM2 patients is strongly discouraged (ADA, 2021). Basal-plus correction is recommended for DM2
patients, even if the patient has poor oral intake, aiming for a target glucose range of 140 to 180 mg/dL
without episodes of hypoglycemia, defined as less than 70 mg/dL (Pasqual & Umpierrez, 2021).
Hypoglycemia management protocols, with tracking, should be reviewed regularly; hospitals will not be
reimbursed for iatrogenic hypoglycemia (ADA, 2016). With respect to primary care, family practice
providers discuss transitions in care and the necessity to include a multidisciplinary approach to improve
the culture of treatment that guides providers away from the current approach of treating only with
sliding-scale insulin (Nau, et al., 2010).
In one meta-analysis on the treatment for hyperglycemia, Seufert (2019) examined 18 reports and
15 studies, following the PRISMA guidelines. A basal-plus insulin regimen was concluded to be the best
management approach for hyperglycemia (Seufert, et al., 2019). Analysis findings showed that the basalplus insulin regimen offered minimal hypoglycemia incidents and that a minor increase in body weight
was associated with the treatment. Timing of the short-acting insulin seemed to have little impact overall
(Seufert, et al., 2019).
A basal-plus insulin protocol was used in a randomized, double-blind study by Meyer (2010), in
which the use of short-acting regular insulin was compared to the use of glulisine, a man-made shortacting insulin. No difference was noted within the first 4 days of hospitalization. After the fourth day, it
was noted that the man-made insulin was associated with slightly fewer hypoglycemic episodes, with
minimally better glycemic control over time (Meyer et al., 2010).
Two studies investigated a basal-bolus technique for hospitalized DM2 patients in which shortacting insulin was eliminated completely (Umpierrez et al., 2007). In another basal-bolus study, patients
were given approximately half of their long-acting glargine at bedtime and the other half divided into
three doses at mealtimes (Umpierrez et al., 2011). Results for patients receiving no short-acting insulin in
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these two studies were significantly less favorable than the results for patients who received a
combination of long-acting and short-acting insulin.
A randomized study (i.e., RABBIT 2) comparing a basal-bolus with a basal-plus insulin
correction regimen provided insulin protocols using both short-acting and long-acting insulin for
hospitalized DM2 patients who were in the medical and surgical units (Umpierrez, Smiley, Hermayer, et
al., 2013). Of the literature review results for the DNP project, the RABBIT 2 study provided the best
results with enough details to reproduce the intervention. Researchers in the study used short-acting
insulin with mealtime and bedtime coverage based on a sliding scale and glucometer reading, in addition
to a long-acting insulin once daily (Umpierrez, Smiley, Hermayer, et al., 2013). Within the RABBIT 2
protocol, weight-based adjustments for the elderly (i.e., over 70 years) and those patients with decreased
renal function (i.e., a serum creatinine > 2mg/dL) were included for the practitioner to easily adjust the
doses (Umpierrez, Smiley, Hermayer, et al., 2013).
Rationale
Wolfe (2001) summarized information found in the Institute of Medicine (IOM) 2001 report
Crossing the Quality Chasm: A New Health Care System for the 21st Century, including the six
dimensions of quality focused primarily to evaluate a health system’s performance. These six dimensions
are part of a five-step agenda to address the shortcomings pointed out in To Err is Human (IOM, 1999),
after that report pointed out that more Americans die from medical mistakes each year than several other
expected leading causes. IOM (2001) identified as Step 1, the six aims for improvement: safe, effective,
patient-centered, timely, efficient, and equitable. Memorable and admirable, these aims are something to
keep in awareness at all times.
The Step 2 strategy, as Wolfe (2001) continued, included 10 guiding rules that focused on the
practitioner and patient relationship. Two of these 10 guiding rules, Number 5 (i.e., evidence-based
decision making) and Number 6 (i.e., safety) stood out as particular strengths of this project. Patient care
should be designed and delivered using the best scientific evidence available and should be safe. The QI
project was expected to be successful because it is based on an evidence-based protocol that has been
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shown to be safe and effective in a randomized trial (Umpierrez, Smiley, Hermayer, et al., 2013).
Furthermore, the findings from the randomized trial were peer reviewed and published, with enough
information to be reproduced safely.
Number 8 in the guiding rules, as Wolfe (2001) outlines, includes the anticipation of patient
needs, which stresses that needs should be anticipated rather than simply being responded to in reacting to
patient events. This DNP project provided a protocol that anticipated the hyperglycemia that DM2
patients often experience during hospitalization (Helmle et al., 2018). Inclusion of a long-acting insulin
protocol was added with the intent to prevent the hyperglycemia from occurring (Umpierrez, Smiley,
Hermayer, et al., 2013).
Wolfe (2001) described Number 9 of the guiding rules found in the IOM (2001) report as a
continuous decrease in waste, that care should not waste resources or the patient’s time. With a focus on
efficiency and safety, this project was intended to provide an improved use of the time of the patient
recovering in the hospital by optimizing blood glucose levels (Umpierrez, Smiley, Hermayer, et al.,
2013). Intending to decrease hyperglycemia, the use of a readily available long-acting insulin resource
was expected to produce improved healing in less time (Ilcewicz et al., 2019).
Frequently, hospitalists and many other providers avoid adding basal insulin, likely due to a
perceived difficulty in calculation and fear regarding hypoglycemia (Draznin et al., 2013). The basal-plus
insulin protocol adds a bedtime dose of long-acting insulin and regular short-acting insulin based on a
sliding scale before meals (Umpierrez, Smiley, Hermayer, et al., 2013). The protocol is relatively
straightforward and simple to order. Several studies confirm that various short-acting insulins may also be
used for the sliding scale: regular insulin, glulisine, lispro, or any other short-acting insulin (Helmle et al.,
2018; Marín-Peñalver et al., 2016; Migdal et al., 2021). For the purposes of this QI project, however, only
regular insulin was used for the short-acting insulin.
Lewin’s Change Model
Kurt Lewin’s (1951) three-step change model was used to plan and organize the practice change
expected in the DNP project. Unfreeze, change, and refreeze are the three simple actions in the model,
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and they provide a well-suited model to create a clinical practice change. Although processes and
outcomes change during the planning, implementation, and evaluation of a project, such changes can be
made more comfortable and logical with the use of Lewin’s anchors (Manchester et al., 2014).
Unfreeze. An initial step is to determine what needs to change. Chaos and disequilibrium invite
change to resting forces, which can be identified as the tacit knowledge acted upon and doing things the
way things have always been done (Malloch, 2017). Unfreezing allows the proposition of new ideas,
improved practice changes, and forward motion to elicit favorable change (Manchester et al., 2014).
For this DNP project, a 10-day reflective practice exercise allowed the examination of why
clinical practice is carried out a certain way and if a better way exists. It was noted in the personal
practice of the DNP student that patients with DM2 who are in the hospital are routinely placed on
sliding-scale insulin yet remain hyperglycemic. Unfreezing occurred by recognizing a change must be
made to safely anticipate the needs of the patient, to use evidence-based decision making, and to not
waste resources or the patient’s time (Wolfe, 2001).
Change. Empowering action, communication, and including others stimulate the drive for change
(Manchester, et al., 2014). Frequent connection, encouragement, and dismissal of negativity are a large
part of dealing with the vulnerable state of change (Lewin, 1951). In addition, supportive leadership and
guidance are strengths to ease the modification phase of this model (Manchester, et al., 2014).
Empowerment by having full practice authority in New Mexico allows a fully unrestricted ability
to act within the scope of a certified nurse practitioner practice. During unfreezing, a needed change was
identified, and now action is the obligation of the practitioner. This DNP project was assigned by the
DNP program director as a solo practice change. During this step, typically one would include others in
the process and encourage their actions with support and communication.
Movement for the practice change is motivated by a desire by the DNP student to improve patient
outcomes. The DNP student noted that DM2 patients were hyperglycemic when treated in the routine
manner of sliding-scale regular insulin only. During a literature review, an evidence-based practice was
found in multiple places (Draznin et al., 2013; Migdal, et al., 2021); it indicated that the sliding scale
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alone is not suitable for glycemic control in the hospital. Standard medical care for inpatient DM2
patients uses strong evidence to include a basal insulin, stressing that it is unsuitable to use short-acting
sliding scale insulin by itself (ADA, 2021). Thus, the DNP student planned a practice change, the
implementation of the basal-plus insulin protocol contained in the RABBIT 2 trial (Umpierrez, Smiley,
Hermayer, et al., 2013), during regular hospitalist practice days. Changing the routine ordering of shortacting sliding scale insulin was initiated, and adding a long-acting basal insulin at bedtime to the DM2
patients’ medication regimen was the change made for a safe, evidence-based favorable practice
adjustment (Umpierrez, Smiley, Hermayer, et al., 2013).
Refreeze. Lewin (1951) indicated that the changes were to be anchored into the culture. Culture
change can be sustained by training and encouraging others to act and use the same steps of unfreezing,
changing, and refreezing. Success should be celebrated; those celebrations act as an encouragement to
continue improvement (Manchester et al., 2014).
Evidence-based, safe practice changes were anchored in the solo practice of the DNP student at
this time. Sustaining this change was not difficult for the student, as the protocol became second nature in
practice. Integrating the change into the GCRMC culture may be achieved by presenting favorable
outcomes to the medical executive committee, along with the evidence provided during the literature
review. Encouragement to implement the basal-plus insulin regimen by writing a safe, patient-centered
local protocol, which is based on the RABBIT 2 results, would be a foundation for refreezing the change
into culture (Umpierrez, Smiley, Hermayer, et al., 2013).
Specific Aims
The aim for this QI DNP project was to decrease hyperglycemia in hospitalized DM2 patients,
maintaining mean blood glucose levels between 70 and 180 mg/dL. Implementation of a safe, evidencebased basal-plus insulin protocol was initiated during regular hospitalist practice to verify whether
improvement in glycemic control could be made.
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Methods

Context
GCRMC is a 94-bed critical access hospital in Alamogordo, Otero County, New Mexico. The
hospitalist service has a staff of 3 physicians and 3 nurse practitioners on duty daily, who see all of the
hospitalized patients admitted to their service during the day. Admissions from the emergency
department, direct admissions from other hospitals, or consults for other services as needed are assigned
on a round-robin rotation basis. One physician hospitalist covers the night shift.
Since COVID-19 emerged, travel nurses have made up the majority of the nursing staff; current
daily staffing is 30 nurses. Unfortunately, the skill set of the travel nursing component is limited, leaving
orders sometimes not carried out and not communicated to the providers. Lack of follow-through and not
following providers’ orders has led to poor outcomes.
This QI project was conducted as a solitary practice change during real-time practice hours by a
DNP student beginning January 21, 2022 and ending February 9, 2022. The immediate supervisor of the
student was continually included and aware of the project, but no other colleagues were aware of the
basal-plus insulin protocol initiated by the student. Colleagues changed the student’s orders without
knowledge of the QI project after patients were handed off during usual continuity of care. This
shortcoming could have been prevented if the Lewin (1951) change framework had been used to a fuller
extent, by including the stakeholders, frequent communication and encouragement, and collaboration in
changing the culture.
Because this DNP project was conducted in a relatively short time period of 21 days, a limited
number of patients were included because their hospitalization extended beyond the time period. With the
results of this QI project being from a small, stand-alone sample, it is anticipated that the QI project can
be repeated with the buy-in of stakeholders, once the small but favorable results are presented. Rewriting
of hospital policy to include the basal-plus insulin protocol is a future possibility.
The PICOT question for the DNP project was formed during a 10-day reflective practice exercise.
During the exercise, the DNP student considered the reasons that the administration of oral
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antihyperglycemic medications is stopped upon the admission of hospitalized DM2 patients and is
substituted with a sliding-scale insulin regimen. A reflective review of the student’s patients within the
electronic medical record (EMR) provided evidence that the DM2 patients treated with a short-acting
insulin sliding scale were not achieving adequate glycemic control during their hospital stay. The
following elements of a PICOT question were formed:
P (Patient, Population, Problem): Noncritically ill hospitalized patients aged 64 to 98 years with
DM2 and hyperglycemia
I (Intervention): Implementation of a basal-plus insulin regimen protocol from the RABBIT 2
trial
C (Current practice): Mean blood glucose levels of admitted patients placed on sliding-scale
short-acting insulin are frequently hyperglycemic
O (Outcome, Objective): Maintain mean blood glucose level to remain between 70 mg/dL and
180 mg/dL
T (Time): 21 days
Intervention
This DNP project was designed to be implemented by the DNP student only. Patients under the
care of the student received the intervention and were tracked throughout their hospitalization. Care was
assumed by one or more of the other hospitalists during the student’s days off. On site, the student’s
direct practice supervisor was aware of the practice change and was kept up to date with any changes. The
nursing staff was not aware of the protocol and was expected to follow the orders as written.
Patients identified by the DNP student as potentially benefiting from the use of a basal-plus
insulin protocol were noncritically ill DM2 adults admitted to the hospital from January 21, 2022 to
February 9, 2022. A detailed basal-plus insulin regimen using both short-acting and long-acting insulin
for hospitalized DM2 patients was documented in the RABBIT 2 trial (Umpierrez, et al., 2013), outlined
below:
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Insulin Glargine Orders
•

Stop oral and noninsulin injected antiglycemic medications on admission.

•

Start insulin glargine total daily dose (TDD): 0.25 units per kg of body weight.

•

Reduce TDD to 0.15 units per kg of body weight if patients are > 70 years old, or if serum
creatinine > 2.0 mg/dL.

•

Administer insulin glargine once daily at the same time of day.

•

Issue an order for sliding-scale short-acting insulin.

•

Administer supplemental short-acting insulin following the sliding-scale protocol for blood
glucose levels >140 mg/dL as shown in Table 1.

•

If the patient is eating, give sliding-scale insulin before each meal and at bedtime. Use the
dose found in “usual” column, shown in Table 1.

•

If the patient is not eating, give sliding-scale insulin every 6 hours. Use the dose found in the
“sensitive” column, shown in Table 1.

Insulin Glargine Adjustment
•

If the fasting and predinner blood glucose level is between 100 mg/dL and 140 mg/dL and no
hypoglycemia is present the previous day, make no changes.

•

If the fasting and predinner blood glucose level is between 140 mg/dL and 180 mg/dL and no
hypoglycemia is present the previous day, increase glargine TDD by 10% every day.

•

If the fasting and predinner blood glucose level is > 180 mg/dL and no hypoglycemia is
present the previous day, increase glargine TDD by 20% every day.

•

If the fasting and predinner blood glucose level is between 70 and 99 mg/dL and no
hypoglycemia is present, decrease glargine TDD by 10% every day.

•

If a patient develops hypoglycemia (blood glucose level < 70 mg/dL), the glargine TDD
should be decreased by 20%.
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Blood Glucose Level Monitoring
•

Blood glucose levels will be measured with a glucometer before each meal and at bedtime if
the patient is eating.

•

Blood glucose levels will be measured every 6 hours if the patient is not eating.

Table 1
Supplemental Sliding-Scale Short-Acting Insulin

Blood
glucose(mg/dL)
141–180
181–220
221–260
261–300
301–350
351–400
>400

Usual
(Eating)
Units
4
6
8
10
12
14
16

Insulin sensitive
(Not eating)
Units
2
4
6
8
10
12
14

Note. Adapted from “A randomized study comparing a basal-bolus with a Basal-plus insulin correction
insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: Basal
plus trial,” by G.E. Umpierrez, D. Smiley, K. Hermayer, A. Kahn, D.E. Olson, C. Newton, S. Jacobs, M.
Rizzo, L. Peng, D. Reyes, I. Pinzon, M.E. Fereira, V. Hunt, A. Gore, M.T. Toyoshima, and V.A. Fonseca,
2013, Diabetes Care, 26(supplementary data, table 1). (https://ada.silverchaircdn.com/ada/content_public/journal/care/36/8/10.2337_dc121988/3/dc121988supplementarydata.pdf?Expires=1652030938&Signature=073~KRNHu9ywsANIAhwWlIxHN5iTF12ResbxUlJYHpFPaWPm3yMRjDgNCt~PAqYwm4DoTHuhEvwFpw~QeOAK00yOvxV0f9H4bns20w3qZnWnQ
Xd4igPXMm9CT46fguwjdccBo4Bn5hc9sSu1BOH7QAt6gYvBVFUHXOYpOQn2ZDDx4NHgfoahLeUKr195msMCzFjruhHLotNe8JNEcFEFQAjtOnBJC5gqqUpdJGTr~G6A9PVO
IfspNaGBsSu43ViNrQkL0HMlMz43ucoLWZRHA5leEfwKOYbUb1sY2dCt5stAFVTZrZy-
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sIWpOzev95-70sGKRRyFtYmjNWffRiw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA). Copyright
2013 by the American Diabetes Association.
Study of the Intervention
The approach of comparing glucose levels of the patients who received the basal-plus insulin
regimen to glucose levels of a similar group of patients who did not receive the regimen was used to
determine whether the outcomes were due to the intervention. Immediately following the intervention
period, information was queried from the electronic medical record (EMR) by a query expert from the
hospital information technology department to obtain mean blood glucose levels during January 21, 2022,
through February 9, 2022. Also included were length of stay, age, and gender of each patient. An identical
query was performed for a similar time frame from the previous year for all DM2 patients treated by the
DNP student. Patients from the previous year did not receive the intervention, and their glucose levels and
some other data were used for comparison to establish the impact of the intervention. All collected
information was given to the DNP student for evaluation.
The mean blood glucose level was calculated using the serum blood glucose level and the pointof-care glucometer readings. The DNP student checked for accuracy of inclusion and exclusion criteria by
manually checking the progress notes of individual patients. Accuracy was ensured by checking the
medication administration record (MAR) for confirmation of protocol adherence. The terms hospital stay
and length of stay are used interchangeably in this document; they apply to the period from admission to
discharge from the hospital.
Plan-Do-Study-Act Cycle
Based on the framework from the model for improvement (Langley et al., 2009), the Plan-DoStudy-Act (PDSA) cycle is included in improvement courses provided by the Institute for Healthcare
Improvement (IHI). Testing a targeted change involves developing a plan to test the change (Plan);
implementing the test (Do); learning, observing, and analyzing the effects of implementing the test
(Study); and establishing which adaptations should be made to the test (Act). Any changes made to the
plan require additional PDSA cycles, with each cycle documenting every change, and each cycle
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improving on the preceding cycle (IHI, 2017). Because of the relatively short intervention time period,
only one PDSA cycle was completed in this QI project.
Measures
Processes chosen to improve quality and safety of care included implementation of the basal-plus
insulin regimen to decrease the mean blood glucose of DM2 patients during hospitalization. In a
retrospective chart query, patients who received the basal-plus insulin regimen were compared to similar
patients from a similar time period a year prior but who did not receive the basal-plus insulin regimen.
Data on the length of stay were also obtained to provide a cost inference.
To assess for completeness and accuracy of the outcomes, progress notes were reviewed by the
DNP student to check for accuracy and completeness. Progress notes were also assessed to identify and
remove patients who were moved to the intensive care unit (ICU) or the COVID-19 unit, were counted
twice, or received high-dose steroids during the study period. Accuracy was assured by careful manual
review of individual patient medication administration records (MAR) by the student for all patients who
initially met the inclusion criteria. This was done to verify the correct administration of the insulin
protocol. Some patients were excluded if their inclusion eligibility changed during the project period.
Analysis
Measurement of information acquired from a QI project includes complexities that are not always
calculable. Several unseen and imprecise actions are present in establishing quality that are not concrete,
or assessable. The simple results gleaned from this project provide a modest attempt from which to draw
inferences.
Results obtained from the data query were examined and organized in an Excel spreadsheet by
the DNP student. Some patients were excluded because they no longer met the inclusion criteria for some
period of time during the DNP project. The mean length of stay and mean blood glucose figures for both
the intervention and nonintervention groups were calculated using the mathematical “mean” function on
Excel. Demographics were manually derived from chart review, and percentage of gender, and mean age
were calculated by hand. Patients included were few in number, so evaluation was not a demanding task.
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Mean blood glucose level during hospitalization was used to determine effectiveness of the
addition of the basal insulin. Elevation of blood glucose level in the hospital setting is multifactorial and
likely was due to unseen variances. Frequently, increased blood glucose level in the hospital environment
can be attributed to the following causes: stress, inactivity, infection or illness, and side effects of
medications (Pasquel & Umpierrez, 2013).
Hospital length of stay was included in the information gathered for analysis, therefore providing
a basis for an inference of cost (Phillips et al., 2017). Length of stay includes hospital admission through
hospital discharge, which can include a multitude of variances by numerous occurrences, diagnoses,
treatments, and conditions. Comparing the length of stay between the intervention group and the
nonintervention group may loosely suggest a correlation between improved outcomes and may be
associated with decreased costs.
Ethical Considerations
This DNP QI project began as a proposal, reviewed and approved by the DNP Chair. Following
approval by the project chair, the DNP student worksite supervisor reviewed the proposal and approved
the project to be conducted at the worksite. GCRMC provided the DNP student with an endorsed letter of
support, which secured the project site (see Appendix A). In addition, the DNP student submitted a QI
project application to the University of Texas at El Paso (UTEP) Institutional Review Board (IRB; see
Appendix B). The IRB reviewed the application and determined that the proposed project did not qualify
as research and that it was a QI project (see Appendix C). Thus, the UTEP IRB exempted this DNP
project from full IRB approval. There were no conflicts of interest to report.
Results
Because this DNP project was conducted starting January 21, 2022 through February 9, 2022, a
relatively short time period, a limited number of patients were included because their hospitalization
extended beyond the time period. With the results of this QI project being from a small, stand-alone
sample, it is anticipated that the QI project can be repeated with the buy-in of stakeholders, once the small
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but favorable results are presented. Rewriting of hospital policy to include the basal-plus insulin protocol
is a future possibility.
Colleagues changed the DNP student’s insulin orders without knowledge of the QI project after
patients were handed off during usual continuity of care. This shortcoming could have been prevented if
the Lewin (1951) change framework had been used to a fuller extent, by including the stakeholders,
frequent communication and encouragement, and collaboration in changing the culture. Future projects
will most likely include input and agreement from stakeholders.
Errors in using the glucometer properly caused erroneously high readings. For instance, the
following glucometer procedure by nursing staff caused erroneously high readings for a patient: wiping
the finger with an alcohol swab, sticking the finger quickly, and squeezing the finger to elicit a drop of
blood for a sample. For one patient, the alcohol wipe was not yet dry; thus, the blood sample was
hemolyzed from the trauma of the squeeze to elicit blood from the vessel. Point-of-care blood glucose
values for that patient were in the mid 200 mg/dL thus, the nurse was treating the patient with insulin in
accordance with a falsely elevated glucometer reading. The serum blood glucose level for this patient was
regularly near 90 mg/dL; however, the false glucometer reading in the 200 mg/dL range was causing the
patient to receive insulin when it was not required. This patient spent an evening in the ICU for close
monitoring, after the overtreatment of insulin resulted in symptomatic hypoglycemia, causing lethargy.
Fortunately, the patient fully recovered and was returned to the medical-surgical floor the next morning.
This patient did not receive any basal insulin and was not included in the results. A clinical reminder was
made for the staff and was discussed with the unit manager, restoring reliability for the floor nursing
practice (Appendix D).
Fifty-one patients with DM2 were followed and treated by the DNP student, the basal-plus insulin
protocol was ordered for these patients. Of the 51 patients, 25 patients were removed from the QI project
due to ICU admission, duplicate entry, or COVID-19 high-dose corticosteroid therapy. These patients
were not included because they did not meet the noncritically ill inclusion criteria. Of the remaining 26
patients, 22 patients were omitted for the following reasons: hospitalist colleagues changed the basal-plus
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insulin protocol on subsequent hospitalization days, one patient declined the glargine injection at bedtime,
or the nurse determined that the glargine dose at bedtime was not appropriate. No hypoglycemic events or
mortality were found during a manual review of progress notes. Four patients received the full basal-plus
insulin protocol regimen during their hospitalization (see Figure 1).
Figure 1
Inclusion and Exclusion of Identified Patients

Comparison was made with four similar DM2 patients under the DNP student’s care at about the
same time the previous year. The patients from the previous year did not receive a basal-plus insulin
regimen. Demographics for the groups were different; mean age was older in the intervention group by
7.25 years, and the intervention group had more female patients, as shown in Table 2.
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Table 2
Mean Age and Gender Composition by Group

Intervention group
Characteristics
n
Age (mean) = 76 years
–
Gender
Female
3
Male
1

%
–
75%
25%

Nonintervention group
Characteristics
n
Age (mean) = 68.75 years –
Gender
Female
2
Male
2

%
–
50%
50%

One of the specific aims was to use the basal-plus insulin protocol to decrease hyperglycemia in
DM2 patients while hospitalized, and the other was to maintain mean blood glucose levels between 70
mg/dL and 180 mg/dL. The mean blood glucose level decreased in the intervention group to 160.98
mg/dL from 186.5 mg/dL in the nonintervention group (see Figure 2). It should be noted that greater than
180 mg/dL is defined as hyperglycemic in this protocol, which was exceeded by the nonintervention
group.
Figure 2
Mean Blood Glucose Level in the Intervention and Nonintervention Groups
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Note. Mean blood glucose values in the intervention group (blue) and nonintervention group (orange).
The horizontal line in each box represents the mean for that group.
Mean length of stay measured in days was compared in the two groups. A decrease by 23% in the
intervention group was realized. Mean length of stay in the nonintervention group was 7.5 days (180
hours), compared to 5.75 days (138 hours) in the intervention group, shown in Figure 3.
Figure 3
Intervention and Nonintervention Length of Stay

Found within the EMR, an hourly telemetry medical-surgical room charge at GCRMC was
$166.025, which included only the hospital room. Mean length of stay for the intervention group was 5.75
days (138 hours), and for the nonintervention group, 7.50 days (180 hours). Hospital room cost for mean
length of stay in the intervention group was $22,911.45, and for the nonintervention group the mean cost
was $29,884.50, shown in Figure 4. The difference is a savings of $6,973.05 for the intervention group.
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Figure 4
Comparison of Mean Costs for Length of Stay for Intervention Group and Nonintervention Group

Discussion
Summary
Because use of the protocol had already been shown to lower blood glucose levels, the expected
result in the DNP project was that the mean blood glucose levels would decrease during hospitalization.
The mean blood glucose level for the intervention group was 160.98 mg/dL, compared to the mean blood
glucose level of 186.5 mg/dL for the nonintervention group. Notably, the nonintervention group’s mean
blood glucose was above the hyperglycemia cutoff value of greater than 180 mg/dL. That the length of
stay decreased by 1.75 days in the intervention group suggests that the basal insulin may have facilitated
an earlier discharge. Overall cost approximately decreased by $6,973.05 for the intervention group, as
inferred from the length of stay. Adding the basal-plus insulin regimen was easy to implement and
maintain, even during a busy hospital day.
Interpretation
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Outcomes from this project do not lend themselves to a direct comparison to the randomized
controlled trial from which the protocol was extracted. The RABBIT 2 trial was a large, multicenter
endeavor with two arms and was powered enough to support multiple measures. Nevertheless, mean
blood glucose levels were reduced in the basal-plus insulin group in both the RABBIT 2 trial and in this
DNP project. The intervention group did not have any hypoglycemic events nor mortalities in the
randomized controlled trial, nor in the DNP project.
Limitations
Since this DNP project was performed by the student only, the results are limited. The positive
results, however, may be presented to the medical executive committee for further consideration for
protocol inclusion. An opportunity to shorten patient healing times, length of stay, cost, and improved
outcomes would be attractive incentives for the hospital to consider.
Several hospitalist colleagues changed the regular insulin sliding scale to a lispro sliding scale.
The use of the short-acting insulin may have slightly varied the result. Some of these patients could have
been included in the project if the protocol included short-acting insulins other than regular insulin. Only
the regular insulin sliding scale was used in this project, and inclusion of other short-acting insulins may
be an addition to include in planning the next cycle. During continuity of care, other providers completely
discontinued or changed the dosage of the basal insulin. Hospitalists’ resistance to change from the
insulin sliding scale has been reported in a few studies (Ilcewicz et al., 2019; Meyer et al., 2010).
Few patients were able to be included in the analysis. With buy-in by the stakeholders, hospitalist
partners, and the floor nursing staff, more patients would be included. Participating and input involving
all stakeholders would likely improve this project.
Conclusions
For the intervention group, success was attained in the reduction of length of stay and cost as well
as in patient mean blood glucose maintenance being below the hyperglycemic level. The straightforward
formula in the basal-plus insulin protocol allowed for easy fine-tuning of basal insulin for elderly patients
or patients with reduced renal function, making the protocol uncomplicated and easy to add to a busy
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hospitalist practice. No hypoglycemic episodes were attributed to use of the basal insulin during this DNP
project. However, fear of hypoglycemia is one reason that hospitalists fail to use anything other than the
short-acting insulin sliding scale (Liu et al., 2017; Nau et al., 2010).
Several comorbidities in noncritically ill patients require more glycemic surveillance.
Hyperglycemia superimposed on pneumonia or chronic obstructive pulmonary disease in hospitalized
patients has been found to increase both length of stay and morbidity (Ferriera et al., 2019). Respiratory
patients typically receive steroid treatment, requiring increased glycemic support. Renal failure and
elderly patients are particularly vulnerable and need insulin adjustments for optimal care (Wang &
Draznin, 2013).
In 2008, Medicare stopped paying for nosocomial diabetic ketoacidosis or for comas due to
hypoglycemia or hyperglycemia (Zhuo, et al., 2015). The basal-plus insulin regimen may be a relatively
simple and effective method to safeguard against the problem. Hospitals and providers have a large
financial stake in initiating effective, evidence-based glycemic protocols, as well as a duty to their
patients (Liu et al., 2017).
Complex decision making for treatment of hospitalized DM2 patients becomes more complicated
as treatment choices increase (Pasquel & Umpierrez, 2021). Elderly patients and those with renal failure
have increased vulnerability, requiring intense, proactive DM2 monitoring as a priority beginning at
hospital admission. The basal-plus insulin regimen provides a solid, relatively simple-to-use structure,
improving hospital practice until other trials and solutions are presented in the future.
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Appendix D

Dear Nursing and Nursing Assistants:

When checking patient glucose with the
glucometers, please remember to:

Allow the finger to dry after using the
alcohol prep pad before sticking the finger

Do not squeeze the finger to get the
blood to come out

Both of these actions cause the glucometer to give a false high reading.
The patient will get insulin when they do not need it

Thank you for your help! Any questions, please ask the nursing educator or the charge nurse.

